Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | SCD | O00767 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | MGLL | Q99685 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3673446 | 0.93 | HSD17B10 (0.53) | L3MBTL1SCDHSD17B10MGLLLMNA | |
| SCHEMBL3669540 | 0.90 | L3MBTL1 (0.49) | L3MBTL1SCDMAPTHSD17B10SMN1; SMN2 | |
| SCHEMBL3674781 | 0.87 | SCD (0.47) | SCDHSD17B10MGLLPANK3RAB9A | |
| SCHEMBL3679255 | 0.86 | POLB (0.58) | L3MBTL1SCDMAPTHSD17B10SMN1; SMN2 | |
| SCHEMBL3672523 | 0.85 | SCD (0.66) | L3MBTL1SCDMAPTHSD17B10SMN1; SMN2 | |
| SCHEMBL3672501 | 0.85 | KDM4E (0.58) | L3MBTL1SCDSMN1; SMN2LMNAPANK3 | |
| SCHEMBL3672562 | 0.84 | SCD (0.54) | SCDMAPTHSD17B10SMN1; SMN2LMNA | |
| SCHEMBL3670643 | 0.83 | SCD (0.49) | L3MBTL1SCDMAPTHSD17B10SMN1; SMN2 | |
| SCHEMBL3667556 | 0.83 | HSD17B10 (0.52) | L3MBTL1SCDHSD17B10MGLLLMNA | |
| SCHEMBL3672187 | 0.82 | SCD (0.50) | SCDSMN1; SMN2MGLLLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1763350-B1 | NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2011-12-21 | — | — | EP | claimed |
| US-20090197894-A1 | NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2009-08-06 | — | — | US | claimed |
| US-20050119251-A1 | Nicotinamide derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2005-06-02 | — | — | US | claimed |
| EP-1763350-B1 | NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2011-12-21 | — | — | EP | disclosed |
| EP-2266566-A2 | Nicotinamide derivatives and their use as therapeutic agents | Xenon Pharmaceuticals Inc. (CA) | 2010-12-29 | — | — | EP | disclosed |
| US-20090197894-A1 | NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2009-08-06 | — | — | US | disclosed |
| US-20070087363-A1 | Therapeutic methods, compounds and compositions | MYRIAD GENETICS, INCORPORATED (US) | 2007-04-19 | — | — | US | disclosed |
| US-20050119251-A1 | Nicotinamide derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119251-A1 | Nicotinamide derivatives and their use as therapeutic agents | NAMPT, NNT, NNMT | L3MBTL1 1863/4885SCD 10/4885MAPT 2923/4885 |
| US-20070087363-A1 | Therapeutic methods, compounds and compositions | APP, BACE1, PSEN1 | L3MBTL1 3373/4885SCD 1186/4885MAPT 7/4885 |
| US-20090197894-A1 | NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | NAMPT, NNT, NNMT | L3MBTL1 1863/4885SCD 10/4885MAPT 2923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.